Pharma BD Deal Intelligence
A $2.9B all-cash acquisition where Bayer's Xofigo radiopharmaceutical bet fell well short of its ~€1B peak-sales target, further undercut by a 2018 safety signal that triggered an FDA/EMA contraindication with abiraterone. Bayer had to acquire additional radiopharma assets in 2021 just to rebuild the prostate-cancer pipeline Algeta was meant to deliver.
Bayer AG secured cancer firm Algeta with a raised $2.9 billion bid; Algeta negotiated a sale price 37% over its share price just ahead of the initial approach.
A few have fretted that the company is paying a bit too much in the deal. 'The takeover price ... appears to be a bit stiff,' DZ Bank analyst Peter Spengler…
BioPharma Dive later documented the ERA-223 trial unblinding for excess fractures and deaths in the Xofigo + Zytiga combination arm — a setback that narrowed…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Bayer agreed to acquire Algeta for ~NKr17.6B (~$2.9B) on a fully-diluted basis, gaining full control of partnered prostate-cancer therapy Xofigo and Algeta's pipeline of targeted alpha radiotherapies; Bayer initial Nov bid was $2.4B, raised to $2.9B in Dec.
Assessment window: 5yr post-close.
334K US cases/yr
Metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases is the lethal end-stage of prostate cancer, where androgen-deprivation therapy has failed and tumor has spread to bone — driving pain, fractures, and high mortality. 5-year survival drops to ~40% in distant-stage disease versus ~100% in localized disease.
At the time of Bayer's December 2013 acquisition of Algeta, mCRPC had become a fiercely contested market following a wave of approvals: Sanofi's Jevtana (cabazitaxel, 2010), J&J's Zytiga (abiraterone, 2011), Dendreon's Provenge (sipuleucel-T, 2010 immunotherapy), and Astellas/Medivation's Xtandi (enzalutamide, 2012). Xofigo (radium-223 dichloride) — co-developed by Bayer and Algeta and approved by FDA in May 2013 — occupied a unique slot as the only alpha-particle-emitting radiopharmaceutical, offering an OS benefit (14.0 vs 11.2 months in ALSYMPCA) without the myelosuppression of beta-emitters like Quadramet. Bayer raised its bid from $2.4B to $2.9B to secure full ownership of both Xofigo's commercial rights and Algeta's broader thorium-227 alpha-emitter platform, viewing the deal as a platform purchase. Analyst views split: Stephen Simpson (Motley Fool) saw Xofigo as a potential $2B drug with ~40% probability of breast and other bone-metastatic indications adding $500M; DZ Bank's Peter Spengler called the price 'a bit stiff.' Xofigo sales subsequently underperformed expectations after the ERA-223 trial (Xofigo + Zytiga) revealed increased fractures and deaths, narrowing its label. (Sources: https://www.fiercepharma.com/m-a/a-sweetened-2-9b-bid-bayer-nabs-its-xofigo-partner-algeta; https://en.wikipedia.org/wiki/Algeta)
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Algeta ASA (this deal) | 2013 | $2.9B | 38 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2013 deals · Bayer AG deals · Oncology deals